Core Insights - Century Therapeutics, Inc. is set to present at the ASGCT 28th Annual Meeting, showcasing its preclinical cell therapy pipeline targeting autoimmune diseases and cancer [1][2] Presentation Details - The first presentation will focus on enhancing solid tumor elimination using a TGF-b neutralizing synthetic receptor in iPSC-derived allogeneic therapies, scheduled for May 13, 2025 [2] - The second presentation will discuss the generation of iPSC-derived CD4+ and CD8+ CD19 CAR ab T cells, demonstrating in vivo tumor control and cell expansion comparable to healthy donor T cells, set for May 17, 2025 [2] Company Overview - Century Therapeutics is a clinical-stage biotechnology company specializing in iPSC-derived cell therapies, aiming to provide significant advantages over existing therapies [3] - The company is committed to developing off-the-shelf cell therapies to enhance patient access and improve treatment outcomes for autoimmune diseases and cancers [3]
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting